Medication info
Kvastin Tablet 5 mg (Rosuvastatin Calcium)

Kvastin Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
FarmGen Science Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202002303 · Approved 2020.04.02 · Insurance code 670104730

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
FarmGen Science Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • stroke risk
  • myocardial infarction risk
  • arterial revascularization risk
View approved original text

This medication is primarily used as an adjunct therapy in patients with primary hypercholesterolemia and mixed hyperlipidemia who cannot be controlled by diet and exercise. It is also utilized as an adjunct to diet in patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia. This drug lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is effective in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. Additionally, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged patients with elevated high-sensitivity C-reactive protein levels and additional cardiovascular disease risk factors. Overall, this medication is used to reduce cardiovascular risk associated with hyperlipidemia and improve cholesterol levels.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This drug should not be used in certain patients. For example, it is contraindicated in patients who are allergic to this drug, have severely impaired liver function, have muscle disorders, have severe renal impairment, are pregnant or breastfeeding women, and in fertile women not using adequate contraception. Moreover, in patients at increased risk for muscle disorders, or when used in conjunction with certain medications, caution should be exercised in deciding the dosage or whether to administer this drug. For instance, patients with moderate to severe renal impairment, those with hypothyroidism, alcoholics, and those with a history of genetic muscle disorders or family history should be cautious. This drug contains lactose, so it should not be given to patients with genetic problems such as lactose intolerance. It is important to perform regular liver function tests and muscle-related tests while taking this drug. Specifically, patients with a history of liver disease or excessive alcohol consumption should regularly monitor liver enzyme levels. In case of symptoms such as myalgia, muscle weakness, or cramps, notify healthcare professionals immediately, and treatment with this drug can be discontinued if necessary. Furthermore, since muscle enzyme levels may increase due to exercise or other causes, caution is needed during testing. This drug can rarely cause severe skin reactions or liver damage, so if symptoms such as rash, fever, or jaundice occur, treatment should be stopped immediately, and healthcare professionals should be consulted. When used in conjunction with other medications, interactions may occur, so all medications being taken should be reported to healthcare professionals with caution. Especially, the risk of muscle injury may increase when combined with certain antiviral agents, immunosuppressants, and fibrate medications. Pregnant or breastfeeding individuals should not use this drug, and women who might become pregnant should use appropriate contraception. In cases of overdose, specific antidotes are not available, so treatment must follow the symptoms, and liver function and muscle enzyme tests are required. Caution is advised during driving or operation of machinery, as dizziness may occur. The drug's concentration may be higher in Asian individuals, so dosage adjustment may be necessary. Overall, this drug should be used with careful monitoring of liver and muscle health status, and it must be taken according to the physician's instructions.

Side effects

Allergic reactions, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced pemphigoid, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also recommended to store the medication at room temperature between 1°C and 30°C. This helps to maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.